(Photo=Celltrion) Celltrion is accelerating its push into Europe’s biosimilar market as Omlyclo, its first-to-market omalizumab biosimilar, gains traction in Spain following a series of public tender wins in key regions. The South Korea–based biopharmaceutical company said its Spanish unit was selected as the top-ranked supplier in a major public procurement tender in Catalonia late last year, marking the product’s first

Photo=Instagram Two prominent South Korean actors are facing growing public scrutiny following media reports alleging aggressive tax practices involving family-owned corporations, renewing debate over how celebrities manage income through closely held entities. Local media reported on February 1 (local time) that actor Kim Seon-ho is under investigation for allegedly using a family-run company to reduce tax liabilities, shortly after similar

Photo=Hyundai Motor Group’ Hyundai Motor Group’s decision not to exercise its buyback option on its former Russian manufacturing plant is fueling speculation that the South Korean automaker may be closing the chapter on Russia—at least for the foreseeable future. The group confirmed earlier this month that it would not repurchase its flagship St. Petersburg factory, a move that effectively rules

(Photo=anua) As competition intensifies in the U.S. skincare market, where product claims have become increasingly interchangeable, brands are searching for ways to differentiate beyond formulation. Anua, a South Korea–based skincare company, is taking that approach by anchoring a global campaign to a collaboration with the Netflix film K-Pop Demon Hunters, using narrative rather than novelty to frame its products. The

Photo=Next Biomedical Next Biomedical Co., a South Korean medical-device specialist, said it has received regulatory approval in Canada for its absorbable embolic microsphere used to treat musculoskeletal pain, a milestone the company says will accelerate its expansion into North America ahead of a planned U.S. launch. The company said on Jan. 29 (local time) that Health Canada granted market authorization